Epstein-barr virus-negative post-transplant lymphoproliferative diseases: three distinct cases from a single center

about

Epstein-barr virus-negative post-transplant lymphoproliferative diseases: three distinct cases from a single center

Item

http://www.wikidata.org/entity/Q37718389

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Epstein-barr virus-negative po ...... nct cases from a single center

@en

Epstein-barr virus-negative po ...... ct cases from a single center.

@nl

type

Item

label

Epstein-barr virus-negative po ...... nct cases from a single center

@en

Epstein-barr virus-negative po ...... ct cases from a single center.

@nl

prefLabel

Epstein-barr virus-negative po ...... nct cases from a single center

@en

Epstein-barr virus-negative po ...... ct cases from a single center.

@nl

P1476

Epstein-barr virus-negative po ...... nct cases from a single center

@en

P2093

Akın Uysal

http://www.w3.org/2001/XMLSchema#string

Gülşah Kaygusuz

http://www.w3.org/2001/XMLSchema#string

Işınsu Kuzu

http://www.w3.org/2001/XMLSchema#string

Kenan Keven

http://www.w3.org/2001/XMLSchema#string

Mutlu Arat

http://www.w3.org/2001/XMLSchema#string

Pervin Topçuoğlu

http://www.w3.org/2001/XMLSchema#string

Sule Mine Bakanay

http://www.w3.org/2001/XMLSchema#string

Sule Sengül

http://www.w3.org/2001/XMLSchema#string

Timur Tunçalı

http://www.w3.org/2001/XMLSchema#string

P2860

Cancers in renal transplant recipients.

Epstein-Barr virus and cancer.

Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial).

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.

Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis.

Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.

Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.

Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant.

P304

79-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4274/TJH.2012.0010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24764734

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

3996636

http://www.w3.org/2001/XMLSchema#string